Published ahead of print on January 18, 2007, doi:10.1164/rccm.200609-1354OC
Am. J. Respir. Crit. Care Med., Volume 175, Number 8, April 2007, 822-828
A more recent version of this article appeared on April 15, 2007
Submitted on September 21, 2006
Accepted on January 18, 2007
Association Between Pulmonary Function and Sputum Biomarkers in Cystic Fibrosis
Nicole Mayer-Hamblett1*, Moira L Aitken2, Frank J Accurso3, Richard A Kronmal4, Michael W Konstan5, Jane L Burns6, Scott D Sagel3, and Bonnie W Ramsey1
1 Department of Pediatrics, University of Washington, Seattle, WA, USA; Children's Hospital and Regional Medical Center, Cystic Fibrosis Foundation Therapeutics Development Network Coordinating Center, Seattle, WA, USA,
2 Department of Medicine, University of Washington, Seattle, WA, USA,
3 Department of Pediatrics, University of Colorado Health Sciences Center, Denver, CO, USA,
4 Children's Hospital and Regional Medical Center, Cystic Fibrosis Foundation Therapeutics Development Network Coordinating Center, Seattle, WA, USA; Department of Biostatistics, University of Washington, Seattle, WA, USA,
5 Rainbow Babies and Children's Hospital and Case Western Reserve University School of Medicine, Cleveland, OH, USA,
6 Department of Pediatrics, University of Washington, Seattle, WA, USA
* To whom correspondence should be addressed. E-mail: nicole.hamblett{at}seattlechildrens.org.
Rationale: Sputum biomarkers of infection and inflammation are noninvasive measures that enable quantification of the complex pathophysiology of cystic fibrosis (CF) lung disease. Validation of these biomarkers as correlates of disease severity is a key step for their application.
Objectives: We constructed a large database from four multi-center studies to quantify the strength of association between expectorated sputum biomarkers and forced expiratory volume in one second (FEV1).
Methods: FEV1 (range 25%-120% predicted) and quantitative data from expectorated sputum biomarkers including free neutrophil elastase, interleukin (IL)-8, neutrophils, Pseudomonas aeruginosa, and Staphylococcus aureus were obtained from 269 participants ages 9-54 from 33 centers. Cross-sectional and longitudinal statistical analyses were performed to estimate associations between the markers and FEV1, including the use of multivariable analyses.
Results: Elastase was negatively correlated with FEV1 (correlation [r] = -0.35, 95% CI:-0.46,-0.22). On average, CF patients who differed in their elastase measurements by 0.5 log differed in their FEV1 values by 7.3% (95% CI: -9.7,-4.6). Neutrophil counts and IL-8 were also each negatively correlated. In a multivariable regression, elastase and neutrophil counts were able to explain the majority of variation in FEV1. Elastase was further shown to have a significant longitudinal association with FEV1, specifically a -2.9% decline in FEV1 (95% CI: -5.0,-0.9) per 1 log increase in elastase. Although correlated with FEV1, bacterial densities were unable to explain clinically meaningful differences in FEV1 within and across patients.
Conclusions: These data support the role of sputum biomarkers as correlates of disease severity in a diverse CF population.
Key words: cystic fibrosis; pulmonary function; sputum; infection; inflammation
This article has been cited by other articles:
|
|
|
|
 
A. K. A. Wright, S. Rao, S. Range, C. Eder, T. P. J. Hofer, M. Frankenberger, L. Kobzik, C. Brightling, J. Grigg, and L. Ziegler-Heitbrock
Pivotal Advance: Expansion of small sputum macrophages in CF: failure to express MARCO and mannose receptors
J. Leukoc. Biol.,
September 1, 2009;
86(3):
479 - 489.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Dufresne, C. Knoop, A. Van Muylem, A. Malfroot, M. Lamotte, C. Opdekamp, G. Deboeck, M. Cassart, B. Stallenberg, G. Casimir, et al.
Effect of Systemic Inflammation on Inspiratory and Limb Muscle Strength and Bulk in Cystic Fibrosis
Am. J. Respir. Crit. Care Med.,
July 15, 2009;
180(2):
153 - 158.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Griese, M. Kappler, A. Gaggar, and D. Hartl
Inhibition of airway proteases in cystic fibrosis lung disease
Eur. Respir. J.,
September 1, 2008;
32(3):
783 - 795.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. J. Blohmke, R. E. Victor, A. F. Hirschfeld, I. M. Elias, D. G. Hancock, C. R. Lane, A. G. F. Davidson, P. G. Wilcox, K. D. Smith, J. Overhage, et al.
Innate Immunity Mediated by TLR5 as a Novel Antiinflammatory Target for Cystic Fibrosis Lung Disease
J. Immunol.,
June 1, 2008;
180(11):
7764 - 7773.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. J. Accurso
Update in Cystic Fibrosis 2007
Am. J. Respir. Crit. Care Med.,
May 15, 2008;
177(10):
1058 - 1061.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Elizur, C. L. Cannon, and T. W. Ferkol
Airway Inflammation in Cystic Fibrosis*
Chest,
February 1, 2008;
133(2):
489 - 495.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Mayer-Hamblett, B. W. Ramsey, and R. A. Kronmal
Advancing Outcome Measures for the New Era of Drug Development in Cystic Fibrosis
Proceedings of the ATS,
August 1, 2007;
4(4):
370 - 377.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. D. Sagel, J. F. Chmiel, and M. W. Konstan
Sputum Biomarkers of Inflammation in Cystic Fibrosis Lung Disease
Proceedings of the ATS,
August 1, 2007;
4(4):
406 - 417.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. W. F. W. Alton, J. C. Davies, and D. M. Geddes
Biomarkers for Cystic Fibrosis: Are We Progressing?
Am. J. Respir. Crit. Care Med.,
April 15, 2007;
175(8):
750 - 751.
[Full Text]
[PDF]
|
|
|
Copyright © 2007 American Thoracic Society
|
|
|
